A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug ...

Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival We performed a single-institution retrospective analysis of patients with R/M HNSCC treated ...

A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and ...

Adding cetuximab (C) to postoperative radiotherapy (RT) improves disease-free survival (DFS) but not overall survival (OS) in intermediate-risk squamous cell carcinoma of the head and neck.

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...

Others attach to cancer cells and help the immune system spot the tumour. One such drug is cetuximab, approved for use in head and neck cancer, which inhibits the EGFR protein on cancer cells ...

More information: Mitchell Machtay et al, Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer, Journal of Clinical Oncology (2025). DOI: 10.1200/JCO-24-01829 ...

In this article, we use the example of head and neck cancer to show how concurrent chemoradiotherapy is used to treat a cancer where locoregional control is central for treatment success.

Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...